ArticleCancer immunity2010
Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.
Article in Cancer immunity, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.Cancer immunology research · 2014Trial
- Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.Leukemia · 2020Article
- Article
- Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.Vaccines · 2017Review
- Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.Current hematologic malignancy reports · 2015Review
- Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens.Iranian journal of cancer prevention · 2015Review
- Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.PloS one · 2015Article
- Immunotherapy strategies for multiple myeloma: the present and the future.Immunotherapy · 2013Review
- MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients.Leukemia · 2013Article
- New strategies in the treatment of multiple myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Review
- Expression of MAGE-C1/CT7 and selected cancer/testis antigens in ovarian borderline tumours and primary and recurrent ovarian carcinomas.Virchows Archiv : an international journal of pathology · 2013Article
- Article
- Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells.PloS one · 2013Article
- NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.Cancer · 2012Article
- MAGE-A3 is highly expressed in a subset of colorectal cancer patients.Cancer immunity · 2012Article
- Immunogenic targets for specific immunotherapy in multiple myeloma.Clinical & developmental immunology · 2012Review
- Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy.Clinical & developmental immunology · 2012Review
- Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.Cancer immunology, immunotherapy : CII · 2011Article
- Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.PloS one · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
The type I melanoma antigen gene (MAGE) proteins CT7 (MAGE-C1) and MAGE-A3 are commonly expressed in multiple myeloma (MM), and their expression correlates with increased plasma cell proliferation and poor clinical outcome. They belong to the cancer-testis antigen (CTAg) group of tumor-associated proteins, some of which elicit spontaneous immune responses in cancer patients. CT7 and MAGE-A3 are promising antigenic targets for therapeutic tumor vaccines in myeloma; therefore, it is critical to determine if they are immunogenic in MM patients. We analyzed cellular and humoral immune responses against CTAgs in patients with plasma cell dyscrasias: MM, monoclonal gammopathy of undetermined significance (MGUS), and Waldenström's macroglobulinemia (WM). Bone marrow lymphocytes from two of four untreated MM patients exhibited CT7-specific cellular immune responses as measured by an autologous cellular immunity assay, the first such immune response to CT7 to be reported in cancer patients. Sera from 24 patients were screened by ELISA for humoral immune responses to CTAgs. Two patients with MM demonstrated positive titers, one for MAGE-A1 and the other for SSX1. These data demonstrate that CTAgs, particularly CT7, are immunogenic in MM patients and merit further exploration as targets of immunological therapy in MM.
Indexed as
Identifiers
20108890PMC2926649W2116109161What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.